Select Publications

Bokemeyer C et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proc ASCO 2007;Abstract 4035.

Cassidy J et al. First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs FOLFOX + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Proc ESMO 2006;Abstract LBA3.

Giantonio BJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44. Abstract

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

National Cancer Institute (NCI). Conquering colorectal cancer: A blueprint for the future. April 2000. No abstract available

O’Connell MJ et al. Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. Proc ASCO 2007;Abstract 4009.

O’Dwyer PJ et al; Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Priorities in colorectal cancer research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
J Clin Oncol 2007;25(16):2313-21. Abstract

Saltz L et al. Bevacizumab in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO 2007;Abstract 4028.

Sobrero AF et al. Randomized Phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Proc AACR 2007;Abstract LB-2.

Van Cutsem E et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc ASCO 2007;Abstract 4000.

Willett CG et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-9. Abstract

 

 

 

 

 

 

Table of Contents

Top of Page